Recognizing comorbidities in AD is critical for effective management. Tailored therapies targeting both AD and its comorbidities, based on shared immunological mechanisms, may improve outcomes. Further research is needed to optimize treatment strategies and explore combination therapies for patients with both AD and comorbid dermatological conditions.